Botanix Pharmaceuticals (BOT) Q1 2025 TU earnings summary

Executive summary

• Sofdra, the first FDA-approved new chemical entity for primary axillary hyperhidrosis, is ready for launch with initial patient experience and digital programs set for Q4 CY2024.

• Key US payer contracts finalized, supporting targeted financial and patient access restrictions, with more contracts expected soon.

• Significant hires in sales, marketing, and operations to support Sofdra commercialization; regional sales managers and field teams to be deployed after January 2025.

• Featured at major investor conferences and held a Commercial Day Webinar to update on launch plans and market insights.

Financial highlights

• Cash balance of A$68.7 million at 30 September 2024 quarter end, with no debt other than trade creditors.

• Net cash used in operating activities was A$10.4 million for the quarter.

• Receipts from customers totaled A$375,000; interest received was A$619,000.

• Proceeds from exercise of options raised A$462,000; net cash used in investing activities was A$763,000.

• Estimated 6.6 quarters of funding available at current cash burn rate.

Outlook and guidance

• First commercial Sofdra prescriptions and refills expected in the coming months, with broader digital launch to follow initial patient program.

• Additional payer contracts anticipated, with updates on coverage percentages to be provided.

• Full sales force deployment and revenue ramp-up expected after January 2025.